By Tebubio, September 2024
Discover how CleanCap® technology is revolutionising mRNA-based therapeutics by enhancing mRNA stability and translation. Get the opportunity to access all the best tools, in one place, for advancing your mRNA therapeutic research thanks to Tebubio.
Over the past few years, mRNA-based therapeutics have emerged as a promising approach to treat various diseases, including cancer, infectious diseases, and genetic disorders. This revolutionary technology works by delivering synthetic mRNA into cells, empowering them to produce therapeutic proteins or antigens tailored to fight specific conditions.
To achieve this, a critical step involves In Vitro Transcription (IVT). IVT synthesizes mRNA using purified RNA polymerase, a DNA template with the target gene, and modified NTPs as building blocks. This precise process produces high-fidelity mRNA tailored for therapeutic proteins, antigens, or gene-editing, highlighting IVT’s crucial role in next-generation therapeutics.
Given its transformative potential in vaccines and gene therapy, IVT of mRNA has gained significant attention in recent years as a key technology driving therapeutic innovations.
This advanced technique enables the production of mRNA molecules outside living cells, enabling precise control over their composition and structure, which is critical for clinical applications.
Plus, a key feature of IVT mRNA is the addition (capping) of a protective cap structure at the 5’ end (5’ cap), which enhances stability and translation by mimicking natural cellular modifications, protecting mRNA from rapid degradation, and improving recognition by the cell’s translation machinery—critical for effective therapeutic use.
IVT Mix Protocol – Transcription Reaction Tabler
As previously mentioned, capping significantly enhances the efficiency of in vitro transcription—essential for therapeutic applications.
TriLink, a pioneer in mRNA research and a long-standing partner, has led innovation in this field. In 2016, they revolutionised capped mRNA production with the introduction of CleanCap® nucleotides.
CleanCap® technology enables co-transcriptional capping with a CAP1 structure during IVT, simplifying the process while ensuring exceptional consistency with nearly 100% capped molecules and minimal batch-to-batch variation. The robustness and efficiency of CleanCap® have set a new standard in mRNA manufacturing, enhancing the stability and translation efficiency of mRNA therapeutics and vaccines.
A reaction of 1 ml would provide 5 mg of capped mRNA. It also means that the smallest reaction with 20 µL would provide 100 µg. This yield is possible for mRNA around 1-3 kb long and only if you use the validated enzymes and buffer.
The Tebubio Contract Research Services (CRS) team would be delighted to assist you with the construction of your plasmid template, offering services such as codon optimisation, gene synthesis, cloning, and plasmid preparation.
Tebubio’s scientific experts can source all the lipids you need for your LNP formulation projects.
Are you interested in CleanCap® Technology?
We offer, all in one place, a comprehensive range of reagents optimised and validated for CleanCap® M6, namely:
Benefit from the best solutions to answer all your needs
You focus on your goals, we take care of all the rest
Global solutions, locally accessible throughout Europe
Full respect of ethical, legal & shipping regulations
2023 © Tebubio all rights reserved
